NCT06398405

A Phase II Clinical Study of Epigallocatechin-3-gallate in Patients With Esophageal Squamous Cancer

Efficacy and Safety of Epigallocatechin-3-gallate, an Important Polyphenolic That Originates From Tea, in Patients With Esophageal Squamous Cancer: A Phase II Trial

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 72 (estimated)
• Sponsor: Shandong Cancer Hospital and Institute · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The investigators conduct this phase II study to evaluate safety and effectiveness of EGCG in patients with dysphagia. Swallowing-related dysphagia and pain scores were recorded using the numerical rating scale (NRS) daily . Barium meal radiography was utilized to measure the luminal size and the length of the lesion area both before and after a week of EGCG treatment. The scales are translated into Chinese and guides in Chinese are developed instructing how to use the scales and perform the assessments.

Conditions

• Esophageal Cancer
• Dysphagia, Esophageal
• Epigallocatechin Gallate

Interventions

Type	Name	Description
OTHER	Epigallocatechin-3-gallate	Epigallocatechin-3-gallate is administered in a solution with a concentration of 4400 umol/L

Timeline

• Start date: 2024-04-22
• Primary completion: 2026-04-22
• Completion: 2026-05-22
• First posted: 2024-05-03
• Last updated: 2024-05-03

Locations

1 site across 1 country: China